Clinical Trial Detail

NCT ID NCT03175224
Title CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation
Recruitment Recruiting
Gender
Phase Phase I
Variant Requirements yes
Sponsors CBT Pharmaceuticals, Inc.
Indications

renal cell carcinoma

gastroesophageal junction adenocarcinoma

stomach carcinoma

Advanced Solid Tumor

non-small cell lung carcinoma

Therapies

CBT-101

Age Groups:

Additional content available in CKB BOOST